8-KCorporate ChangesExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Change in Control (Nov 9, 2012)

Filed November 9, 2012For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on November 8, 2012, primarily to announce a significant addition to its Board of Directors. Dr. A. Eugene Washington, M.D., M.Sc., was appointed to the board, effective November 6, 2012. Dr. Washington brings extensive experience in health sciences, medical education, and healthcare system leadership, serving as Vice Chancellor of Health Sciences and Dean at UCLA's David Geffen School of Medicine, and CEO of the UCLA Health System. This appointment is noteworthy as it adds a respected figure in the medical and academic community to JNJ's leadership. Investors should view this as a strategic move to enhance the board's expertise, particularly in areas relevant to the company's core pharmaceutical and medical device businesses. Dr. Washington will serve as a non-employee director and will be compensated according to the company's standard director compensation policies as detailed in its 2012 Proxy Statement.

Key Highlights

  • 1Appointment of Dr. A. Eugene Washington to the Johnson & Johnson Board of Directors, effective November 6, 2012.
  • 2Dr. Washington's extensive background includes leadership roles at UCLA, such as Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine, and CEO of the UCLA Health System.
  • 3His expertise spans health sciences, medical education, and healthcare system management, which is highly relevant to JNJ's industry.
  • 4Dr. Washington will serve as a non-employee director.
  • 5Compensation for Dr. Washington will align with the company's established director compensation practices outlined in the 2012 Proxy Statement.
  • 6The announcement was made via an attached press release (Exhibit 99.1).

Frequently Asked Questions

Dr. A. Eugene Washington is a highly respected figure in health sciences and medical leadership. He holds significant positions at UCLA, including Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine, and CEO of the UCLA Health System. His appointment to the Johnson & Johnson Board of Directors likely aims to leverage his deep expertise in healthcare, medicine, and health policy to inform the company's strategic decisions.

Dr. Washington's appointment is a strategic addition to the board, bringing valuable experience and perspective from the academic medical and healthcare delivery sectors. This can enhance the board's oversight and guidance, particularly concerning innovation, research and development, and market trends within the pharmaceutical and medical device industries.

As a non-employee director, Dr. Washington will receive compensation in accordance with Johnson & Johnson's standard director compensation policies. Specific details regarding this compensation are available in the 'Director Compensation' section of the company's 2012 Proxy Statement.